TipRanks on MSN

Lexaria Bioscience achieves primary endpoint in Phase 1b study GLP-1-H24-4

Lexaria Bioscience (LEXX) provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week ...

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Lexaria says its oral GLP-1 cut total adverse events nearly 48% versus Novo's Rybelsus, with comparable HbA1c results in a Phase 1b study.

Lexaria Bioscience Corp.: Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the follo ...

Primary Endpoint Successfully Achieved in Lexaria’s Phase 1b Study GLP-1-H24-4

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings ...